E-drug: Abbott reduces ARV prices (cont)
MSF would like to point out a few additions and corrections to the
table of reduced antiretroviral prices published in the Wall Street
Journal article copied to the list yesterday.
The Wall Street Journal table should be completed with another very important
offer. Aurobindo (generic manufacturer in India) has recently offered a triple
therapy regimen (namely zidovudine, lamivudine and nevirapine) at
$295 per year per patient. A letter describing this offer has been
sent recently to WHO (Dr. Brundtland), UNAIDS (Dr. Piot), the
European Commission (Poul Nielson, Romano Prodi), and to the
Southern African Development Corporation (SADC) (Dr. T. Balfour).
The letter was copied to MSF as well.
Aurobindo Pharma has also been able to develop other antiretrovirals
to those listed above: nelfinavir, indinavir sulfate, efavirenz, saquinavir,
didanosine, and stavudine.
Furthermore, there should be a correction to the table: Cipla's, Hetero's, and
Aurobindo's offers are not restricted to sub-Saharan Africa. There are no
Pharmacist, Access to Essential Medicines Campaign
Medecins Sans Frontieres
Send mail for the `E-Drug' conference to `email@example.com'.
Mail administrative requests to `firstname.lastname@example.org'.
For additional assistance, send mail to: `email@example.com'.